Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.

Journal of translational autoimmunity·2026
Same author

Time-dependent effects of interleukin-1 blockade by anakinra in myocarditis and inflammatory cardiomyopathy.

European journal of heart failure·2026
Same author

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.

RMD open·2026
Same author

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.

RMD open·2026
Same author

Synovial biopsy and tissue sampling in the management of RA.

Rheumatology (Oxford, England)·2026
Same author

Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database.

Rheumatology (Oxford, England)·2026

Related Experiment Video

Updated: Jun 2, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

B cells in systemic sclerosis: a possible target for therapy.

Silvia Bosello1, Giacomo De Luca, Barbara Tolusso

  • 1Division of Rheumatology, Catholic University, Medical School, Rome, Italy.

Autoimmunity Reviews
|May 7, 2011
PubMed
Summary

B cells play a key role in systemic sclerosis (SSc), a fibrotic autoimmune disease. Targeting B cells, particularly with anti-CD20 therapy, shows promise for treating SSc by reducing fibrosis and immune activation.

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jun 2, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Systemic sclerosis (SSc) is an autoimmune disease marked by excessive extracellular matrix (ECM) deposition and immune activation.
  • Evidence suggests B cells contribute to tissue fibrosis and autoimmunity in SSc.
  • B cells in SSc patients exhibit chronic activation and specific abnormalities, including increased CD19 expression.

Purpose of the Study:

  • To investigate the role of B cells in the pathogenesis of systemic sclerosis.
  • To explore the potential of targeting B cells as a therapeutic strategy for SSc.

Main Methods:

  • Analysis of B cell abnormalities in SSc patients and tight-skin mouse models.
  • Evaluation of the effects of B cell depletion (anti-CD20 antibody) in animal models.
  • Review of clinical data on anti-human CD20 antibody (Rituximab) therapy in SSc patients.

Main Results:

  • B cell abnormalities, including chronic activation and increased CD19 expression, are present in SSc.
  • B cell depletion in tight-skin mice ameliorates skin hyperplasia and autoimmunity.
  • Rituximab therapy shows potential benefits for skin fibrosis and lung involvement in SSc patients, with a favorable safety profile.

Conclusions:

  • B cells are implicated in the development and progression of systemic sclerosis.
  • Targeting B cells, specifically via anti-CD20 therapy, represents a potential therapeutic approach for SSc.
  • Further investigation into anti-CD20 treatments for SSc is warranted.